What Medtronic Ltd does

Medtronic Ltd is the UK operating entity of Medtronic plc (NYSE: MDT), trading under the consumer-facing MiniMed brand and headquartered in Watford, Hertfordshire. The entity operates Medtronic's diabetes business for the United Kingdom only, with related manufacturing at Medtronic MiniMed Inc. (US) and EMEA distribution coordinated through Medtronic International Trading sàrl (Switzerland) and Medtronic BV (Netherlands). Its core offering is an integrated diabetes management ecosystem spanning insulin pump therapy (MiniMed 780G with SmartGuard auto-adjusting algorithm), continuous glucose monitoring (Guardian 4, Simplera), smart insulin pens (InPen, MiniMed Go), and a broad infusion set and reservoir portfolio including the first 7-day wear Extended infusion set. Underlying these devices are the CareLink Personal data platform for therapy reporting and the WeCare personalized onboarding and 24/7 support program, which together aggregate pump, CGM, and pen data from a large installed base.

The business model is a hybrid of regulated medical device hardware sales and recurring software/services revenue. Hardware revenue comes from pump, CGM, smart pen, reservoir, and infusion set sales, with the Extended infusion set and matching reservoir creating a weekly rather than twice-weekly consumables cycle. Software and services revenue is generated through CareLink Personal and the WeCare subscription-style support program. Distribution is dual-track: NHS-funded devices are prescribed and initiated through healthcare professionals (HCPs), with a dedicated HCP portal at hcp.medtronic-diabetes.com, while self-funded patients purchase directly through the UK eShop (self-funded-shop.medtronic-diabetes.co.uk). Customer segments are primarily people with Type 1 diabetes on pump therapy, people with Type 2 diabetes on multiple daily injections (addressed via Smart MDI and MiniMed Go), and the HCPs who prescribe and manage them. The UK entity employs 125 people and operates in a single geography, with growth dependent on NHS commissioning, NICE guideline evolution, and direct-to-consumer channel scaling.

Name

Medtronic Ltd

Legal name

Medtronic Limited

Website

https://medtronic-diabetes.com

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

Medtronic Ltd is the UK subsidiary of Medtronic plc, trading as MiniMed. It distributes an integrated diabetes ecosystem — insulin pumps, CGMs, smart pens, and the CareLink data platform — serving Type 1 and Type 2 diabetes patients in the UK via NHS and direct eShop channels.

Ownership category

akta.pro rank

Product category

Diabetes Management Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industries

Insulin Pumps & Patch Pumps (HLAHAIAG), Insulin Pumps (Tubed) (HLAHAHAB), Smart Insulin Pens & Connected Pen Caps (HLAHAHAD), Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

Keywords

• Insulin pump therapy
• Continuous glucose monitoring
• Diabetes management devices
• Smart insulin pen
• Hybrid closed loop systems

Headquarters

HQ city

Watford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Hardware Sales: Sale of insulin pumps (MiniMed 780G, MiniMed 640G, MiniMed 670G), continuous glucose monitors, smart insulin pens, infusion sets, and consumables through direct eShop channel and healthcare provider prescriptions.
2. Software and Data Services: CareLink Personal cloud platform for device data management, WeCare support services providing personalized onboarding and 24/7 assistance, and mobile app ecosystem.
3. Extended Infusion Set and Reservoir Consumables: Proprietary 7-day Extended Infusion Set and matching 3.0ml reservoir designed exclusively for use with the Medtronic Extended system, requiring weekly rather than twice-weekly changes.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Medtronic Ltd operates the UK diabetes business under the MiniMed brand, designing, manufacturing, and selling insulin pumps (MiniMed 780G system), continuous glucose monitors (Guardian 4 and Simplera), the InPen smart insulin pen, infusion sets (Mio Advance, Mio 30, Quick-set, Silhouette, Sure-T, Extended), reservoirs, and supporting software platforms (CareLink Personal, WeCare, MiniMed Mobile and CareLink Connect apps) for people with Type 1 and insulin-requiring Type 2 diabetes.

Product overview

Medtronic Ltd (trading as MiniMed) is the insulin delivery division of Medtronic, offering an integrated ecosystem of diabetes management products. The core offering is the MiniMed 780G system — a hybrid closed-loop insulin pump that automatically adjusts basal insulin delivery based on CGM data. For patients preferring multiple daily injections, the Smart MDI system combines Simplera CGM with the InPen smart insulin pen. The product portfolio spans multiple device categories: insulin pumps (MiniMed 780G), smart insulin pens (InPen, MiniMed Go), CGM sensors (Guardian 4, Simplera), infusion sets (Medtronic Extended, Mio Advance, Mio 30, Quick Set, Silhouette, Sure-T), reservoirs, and injection ports (i-Port Advance). These devices are unified through the CareLink data management platform, which aggregates pump, CGM, and smart pen data for patients and healthcare providers, and supported by the WeCare patient onboarding and support program.

Differentiator

Problem solved

Functional benefit

Brands

• WeCare: Personalised onboarding programs and 24/7 support services for diabetes patients using Medtronic devices.
• CareLink
• MiniMed 780G System
• MiniMed Go System
• Simplera CGM
• InPen Smart Insulin Pen
• Guardian 4 System
• SmartGuard

Products and services

• MiniMed 780G System Automated insulin delivery system for people with Type 1 diabetes, combining an insulin pump, CGM integration, and a hybrid closed-loop control algorithm to automatically adjust basal insulin and correct highs.
• Smart MDI System Connected insulin pen and CGM-based system for people with insulin-requiring diabetes who manage their condition with multiple daily injections rather than a pump.
• InPen System Bluetooth-enabled smart insulin pen that records insulin doses, calculates dose recommendations, and shares data with the companion mobile app for MDI users.
• Guardian 4 Sensor Continuous glucose monitoring sensor that provides real-time interstitial glucose readings and integrates with Medtronic insulin pumps and smart pen systems.
• Simplera Sensor Continuous glucose monitoring sensor positioned by Medtronic for UK users who want CGM data without the full pump-based closed-loop system.
• MiniMed Extended Infusion Set Extended-wear insulin infusion set designed to be used for a longer duration than standard sets, used as a consumable with Medtronic insulin pumps.
• MiniMed Mio Advance Infusion Set Pre-loaded, serter-based insulin infusion set that simplifies insertion for pump users as a pump consumable.
• MiniMed Mio 30 Infusion Set Angled (30°) infusion set consumable for Medtronic insulin pump users requiring angled insertion.
• MiniMed Quick-Set Infusion Set 90-degree quick-insertion infusion set used as a standard consumable with Medtronic insulin pumps.
• MiniMed Silhouette Infusion Set Variable-angle, variable-depth infusion set consumable for Medtronic insulin pump users.
• MiniMed Sure-T Infusion Set Steel-cannula infusion set consumable for Medtronic insulin pump users who prefer or require a steel cannula.
• MiniMed Reservoirs Insulin reservoir cartridges used as consumables to fill Medtronic insulin pumps.
• i-Port Advance Injection port device that allows people on multiple daily injections to take their shots through a single inserted port rather than multiple skin punctures.
• CareLink Personal Online diabetes data management platform that lets patients and clinicians review insulin pump, CGM, and Smart MDI therapy data and generate reports.
• WeCare Subscription-style patient support program that helps new pump and CGM users get started, including onboarding, training, and ongoing assistance.

Quantifiable outcome

• Users achieve mean 80% Time In Range (TIR) with MiniMed 780G using recommended settings
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration20 records

Feature8 records

Partnerships

One partnership is on record.

• National Health Service (NHS)coreOthersMedtronic Diabetes benefits from NHS NICE guideline recommendations that call for increased access to diabetes technology including CGM and insulin pump therapy for people with Type 1 and Type 2 diabetes. The updated NICE guidelines (NG17, NG18, NG28) recommend offering real-time CGM and choice of monitoring technologies, potentially expanding the patient population eligible for Medtronic devices through NHS commissioning.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sanofi: Sanofi is a major diabetes pharmaceutical company that is expanding into digital health and connected diabetes solutions, positioning it as a broad incumbent that intersects with Medtronic's UK diabetes patient ecosystem.
• Novo Nordisk: Novo Nordisk is a global diabetes leader whose insulin insulins (e.g., NovoRapid, Fiasp) are explicitly supported by Medtronic's InPen, and which is increasingly expanding into connected diabetes devices, making it an adjacent incumbent in the UK diabetes space.
• Roche Diabetes Care: Roche Diabetes Care offers the Accu-Chek portfolio of blood glucose meters, insulin pumps, and digital diabetes management tools, overlapping with Medtronic's diabetes ecosystem in the UK and other European markets.
• Eli Lilly: Eli Lilly is a global diabetes leader with insulin and emerging connected delivery offerings, making it a broad incumbent whose products and digital strategy intersect with Medtronic's UK diabetes market.

Direct peers

• Ypsomed: Ypsomed manufactures the mylife YpsoPump insulin pump and is a direct competitor to Medtronic's tubed insulin pump portfolio in the UK and European diabetes care market.
• Tandem Diabetes Care: Tandem Diabetes Care produces the t:slim X2 insulin pump with Control-IQ AID algorithm, directly competing with Medtronic's MiniMed 780G in the hybrid closed-loop pump segment across the UK and Europe.
• Dexcom: Dexcom is a leading continuous glucose monitor (CGM) manufacturer (G6, G7) that directly competes with Medtronic's Guardian 4 and Simplera CGM systems and is increasingly integrated with multiple AID pump platforms, including in the UK market.
• Abbott Diabetes Care: Abbott manufactures the FreeStyle Libre family of CGM sensors, the dominant CGM brand in the UK and a direct competitor to Medtronic's Guardian 4 and Simplera for both Type 1 and Type 2 diabetes patients.
• Insulet Corporation: Insulet's OmniPod 5 is a tubeless patch pump with AID capability, directly competing with Medtronic's MiniMed 780G and offering a form-factor alternative in the UK and European insulin pump market.

Emerging players

• CamDiab: CamDiab develops the CamAPS FX closed-loop algorithm that is interoperable with multiple insulin pumps and CGMs, representing an emerging software layer that could substitute for Medtronic's proprietary SmartGuard and CareLink algorithm stack.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@MiniMed_EU
• Facebookfacebook.com/MiniMedUKandIreland
• Instagraminstagram.com/minimeduk
• TikToktiktok.com/@minimed_eu
• LinkedInlinkedin.com/company/medtronic-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medtronic Ltd